<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://www.fda.gov/oc/datacouncil/stylesheets/spl/spl.xsl" type="text/xsl"?><document xmlns="urn:hl7-org:v3" xmlns:voc="http://www.hl7.org/v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.fda.gov/oc/datacouncil/schemas/spl/spl.xsd">
<id root="FFA8164B-E697-42A4-C8A7-22FB3B26B8AF" />
<code code="34391-3" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="HUMAN PRESCRIPTION DRUG LABELING" />
<title mediaType="text/x-hl7-title+xml">DIURIL&#174; ORAL SUSPENSION <br />(CHROLOTHIAZIDE)</title>
<effectiveTime value="20060413" />
<setId root="FFA8164B-E697-42A4-C8A7-22FB3B26B8AF" />
<versionNumber value="2" />
<author>
  <time/>
  <assignedEntity>
   <representedOrganization>
    <name>Merck and Co., Inc.</name>
   </representedOrganization>
  </assignedEntity>
</author>
<component>
<structuredBody>
<component>
<section>
<id root="2A3A0A27-63A9-A5C6-15E9-2B418A20D95F" />
<effectiveTime value="20060413" />
<subject>
<manufacturedProduct>
<manufacturedMedicine>
<code code="0006-3239" codeSystem="2.16.840.1.113883.6.69" />
<name>Diuril</name>
<formCode code="C42994" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION" />
<activeIngredient>
<quantity>
<numerator unit="mg" value="250">
<translation code="C28253" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLIGRAM" value="250" />
</numerator>
<denominator unit="mL" value="5">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="5" />
</denominator>
</quantity>
<activeIngredientSubstance>
<code code="77W477J15H" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>chlorothiazide</name>
<activeMoiety>
<activeMoiety>
<code code="77W477J15H" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>chlorothiazide</name>
</activeMoiety>
</activeMoiety>
</activeIngredientSubstance>
</activeIngredient>
<asEntityWithGeneric>
<genericMedicine>
<name>chlorothiazide</name>
</genericMedicine>
</asEntityWithGeneric>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>alcohol</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="8SKN0B0MIM" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>benzoic acid</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>D&amp;C Yellow 10</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>flavors</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>glycerin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>methylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>propylparaben</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>purified water</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>sodium saccharin</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9" codeSystemName="FDA SRS" />
<name>sucrose</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<inactiveIngredient>
<inactiveIngredientSubstance>
<name>tragacanth</name>
</inactiveIngredientSubstance>
</inactiveIngredient>
<asContent>
<quantity>
<numerator unit="mL" value="237">
<translation code="C28254" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MILLILITER" value="237" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code />
<formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" />
<asContent>
<quantity>
<numerator value="1">
<translation code="C48477" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE" value="1" />
</numerator>
<denominator value="1">
<translation value="1" />
</denominator>
</quantity>
<containerPackagedMedicine>
<code code="0006-3239-66" codeSystem="2.16.840.1.113883.6.69" />
<formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON" />
</containerPackagedMedicine>
</asContent>
</containerPackagedMedicine>
</asContent>
</manufacturedMedicine>
<consumedIn>
<substanceAdministration>
<routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL" />
</substanceAdministration>
</consumedIn>
</manufacturedProduct>
</subject>
</section>
</component>
<component>
<section>
<id root="4AA67C5F-DD5D-9C5E-1C4F-B782E8285F4E" />
<code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DESCRIPTION</content></title>
<text><paragraph>DIURIL<footnote ID="footnote1">Registered trademark of MERCK&amp; CO., Inc. <br />COPYRIGHT &#169; MERCK &amp; CO., Inc., 1986<br />  All
rights reserved</footnote> (Chlorothiazide) is a diuretic and antihypertensive.
It is 6-chloro-2<content styleCode="italics">H</content>-1,2,4-benzothiadiazine-7-sulfonamide
1,1-dioxide. Its empirical formula is C<sub>7</sub>H<sub>6</sub>ClN<sub>3</sub>O<sub>4</sub>S<sub>2</sub> and
its structural formula is:</paragraph><renderMultiMedia referencedObject="MM1135783106-1"><caption />
</renderMultiMedia><paragraph>It is a white, or practically
white, crystalline powder with a molecular weight of 295.72, which is very
slightly soluble in water, but readily soluble in dilute aqueous sodium hydroxide.
It is soluble in urine to the extent of about 150&#160;mg per 100&#160;mL
at pH&#160;7.</paragraph><paragraph>Oral Suspension DIURIL contains 250&#160;mg
of chlorothiazide per 5&#160;mL, alcohol 0.5 percent, with methylparaben 0.12
percent, propylparaben 0.02 percent, and benzoic acid 0.1 percent added as
preservatives. The inactive ingredients are D&amp;C Yellow&#160;10, flavors,
glycerin, purified water, sodium saccharin, sucrose and tragacanth.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<observationMedia ID="MM1135783106-1">
<id root="CC96E7A7-5ED7-4D20-7695-5702ACED165E" />
<value mediaType="image/jpeg" xsi:type="ED"><reference value="diuril_os-figure-01.jpg" /></value>
</observationMedia>
</component>
</section>
</component>
<component>
<section>
<id root="70A605B9-E54C-918C-D9AF-5BB51DEED8C4" />
<code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">CLINICAL PHARMACOLOGY</content></title>
<text><paragraph>The mechanism of the antihypertensive effect of thiazides
is unknown. DIURIL does not usually affect normal blood pressure.</paragraph><paragraph>DIURIL
affects the distal renal tubular mechanism of electrolyte reabsorption. At
maximal therapeutic dosage all thiazides are approximately equal in their
diuretic efficacy.</paragraph><paragraph>DIURIL increases excretion of sodium
and chloride in approximately equivalent amounts. Natriuresis may be accompanied
by some loss of potassium and bicarbonate.</paragraph><paragraph>After oral
use diuresis begins within 2 hours, peaks in about 4 hours and lasts about
6 to 12 hours.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<section>
<id root="FB297C64-7E65-7F61-4E28-EAB6CBAA3AE7" />
<title mediaType="text/x-hl7-title+xml">Pharmacokinetics and Metabolism</title>
<text><paragraph>DIURIL is not metabolized but is eliminated rapidly by the
kidney. The plasma half-life of chlorothiazide is 45-120 minutes. After oral
doses, 10-15 percent of the dose is excreted unchanged in the urine. Chlorothiazide
crosses the placental but not the blood-brain barrier and is excreted in breast
milk.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="F1CA1249-B047-5490-9D7C-EE9726C47867" />
<code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS AND USAGE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content ID="Indications" styleCode="bold">INDICATIONS AND USAGE</content></title>
<text><paragraph>DIURIL is indicated as adjunctive therapy in edema associated
with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen
therapy.</paragraph><paragraph>DIURIL has also been found useful in edema
due to various forms of renal dysfunction such as nephrotic syndrome, acute
glomerulonephritis, and chronic renal failure.</paragraph><paragraph>DIURIL
is indicated in the management of hypertension either as the sole therapeutic
agent or to enhance the effectiveness of other antihypertensive drugs in the
more severe forms of hypertension.</paragraph><paragraph><content styleCode="italics">Use
in Pregnancy. </content>Routine use of diuretics during normal pregnancy is
inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics
do not prevent development of toxemia of pregnancy and there is no satisfactory
evidence that they are useful in the treatment of toxemia.</paragraph><paragraph>Edema
during pregnancy may arise from pathologic causes or from the physiologic
and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy
when edema is due to pathologic causes, just as they are in the absence of
pregnancy (see <linkHtml href="#Precautions_Pregnancy">PRECAUTIONS, Pregnancy</linkHtml>).
Dependent edema in pregnancy, resulting from restriction of venous return
by the gravid uterus, is properly treated through elevation of the lower extremities
and use of support stockings. Use of diuretics to lower intravascular volume
in this instance is illogical and unnecessary. During normal pregnancy there
is hypervolemia which is not harmful to the fetus or the mother in the absence
of cardiovascular disease. However, it may be associated with edema, rarely
generalized edema. If such edema causes discomfort, increased recumbency will
often provide relief. Rarely this edema may cause extreme discomfort which
is not relieved by rest. In these instances, a short course of diuretic therapy
may provide relief and be appropriate.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="2A247755-C5AC-BF93-992D-26293FFF70E1" />
<code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">CONTRAINDICATIONS</content></title>
<text><paragraph>Anuria.</paragraph><paragraph>Hypersensitivity to this product
or to other sulfonamide-derived drugs.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="3C1DCD47-97F6-8A4B-5FAD-CD85824EEF41" />
<code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content ID="Warnings" styleCode="bold">WARNINGS</content></title>
<text><paragraph>Use with caution in severe renal disease. In patients with
renal disease, thiazides may precipitate azotemia. Cumulative effects of the
drug may develop in patients with impaired renal function.</paragraph><paragraph>Thiazides
should be used with caution in patients with impaired hepatic function or
progressive liver disease, since minor alterations of fluid and electrolyte
balance may precipitate hepatic coma.</paragraph><paragraph>Thiazides may
add to or potentiate the action of other antihypertensive drugs.</paragraph><paragraph>Sensitivity
reactions may occur in patients with or without a history of allergy or bronchial
asthma.</paragraph><paragraph>The possibility of exacerbation or activation
of systemic lupus erythematosus has been reported.</paragraph><paragraph>Lithium
generally should not be given with diuretics (see <linkHtml href="#Precautions_DrugInteractions">PRECAUTIONS,
Drug&#160;Interactions</linkHtml>).</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="74B10816-76BD-3638-C9E7-9CCE1F51B17C" />
<code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content ID="Precautions" styleCode="bold">PRECAUTIONS</content></title>
<text />
<effectiveTime value="20060413" />
<component>
<section>
<id root="C573D2DE-B855-7F9B-1088-D9F920DE1648" />
<code code="34072-9" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="General Precautions" />
<title ID="Precautions_General" mediaType="text/x-hl7-title+xml">General </title>
<text><paragraph>All patients receiving diuretic therapy should be observed
for evidence of fluid or electrolyte imbalance: namely, hyponatremia, hypochloremic
alkalosis, and hypokalemia. Serum and urine electrolyte determinations are
particularly important when the patient is vomiting excessively or receiving
parenteral fluids. Warning signs or symptoms of fluid and electrolyte imbalance,
irrespective of cause, include dryness of mouth, thirst, weakness, lethargy,
drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular
fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances
such as nausea and vomiting.</paragraph><paragraph>Hypokalemia may develop,
especially with brisk diuresis, when severe cirrhosis is present or after
prolonged therapy.</paragraph><paragraph>Interference with adequate oral electrolyte
intake will also contribute to hypokalemia. Hypokalemia may cause cardiac
arrhythmias and may also sensitize or exaggerate the response of the heart
to the toxic effects of digitalis (e.g., increased ventricular irritability).
Hypokalemia may be avoided or treated by use of potassium-sparing diuretics
or potassium supplements such as foods with a high potassium content.</paragraph><paragraph>Although
any chloride deficit is generally mild and usually does not require specific
treatment except under extraordinary circumstances (as in liver disease or
renal disease), chloride replacement may be required in the treatment of metabolic
alkalosis.</paragraph><paragraph>Dilutional hyponatremia may occur in edematous
patients in hot weather; appropriate therapy is water restriction, rather
than administration of salt, except in rare instances when the hyponatremia
is life-threatening. In actual salt depletion, appropriate replacement is
the therapy of choice.</paragraph><paragraph>Hyperuricemia may occur or acute
gout may be precipitated in certain patients receiving thiazides.</paragraph><paragraph>In
diabetic patients dosage adjustments of insulin or oral hypoglycemic agents
may be required. Hyperglycemia may occur with thiazide diuretics. Thus latent
diabetes mellitus may become manifest during thiazide therapy.</paragraph><paragraph>The
antihypertensive effects of the drug may be enhanced in the post-sympathectomy
patient.</paragraph><paragraph>If progressive renal impairment becomes evident,
consider withholding or discontinuing diuretic therapy.</paragraph><paragraph>Thiazides
have been shown to increase the urinary excretion of magnesium; this may result
in hypomagnesemia.</paragraph><paragraph>Thiazides may decrease urinary calcium
excretion. Thiazides may cause intermittent and slight elevation of serum
calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia
may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued
before carrying out tests for parathyroid function.</paragraph><paragraph>Increases
in cholesterol and triglyceride levels may be associated with thiazide diuretic
therapy.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="EEC2597A-7492-6F23-3DE3-3C03F0A915DA" />
<code code="34075-2" codeSystem="2.16.840.1.113883.6.1" displayName="LABORATORY TESTS SECTION" />
<title mediaType="text/x-hl7-title+xml">Laboratory Tests</title>
<text><paragraph>Periodic determination of serum electrolytes to detect possible
electrolyte imbalance should be done at appropriate intervals.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="Precautions_DrugInteractions">
<id root="ECB596D1-B89F-CA0B-CE55-AEA9BC076EF5" />
<code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">Drug Interactions</title>
<text><paragraph>When given concurrently the following drugs may interact
with thiazide diuretics.</paragraph><paragraph><content styleCode="italics">Alcohol,
barbiturates, or narcotics&#160;</content>- potentiation of orthostatic hypotension
may occur.</paragraph><paragraph><content styleCode="italics">Antidiabetic
drugs </content>(oral agents and insulin)&#160;- dosage adjustment of the
antidiabetic drug may be required.</paragraph><paragraph><content styleCode="italics">Other
antihypertensive drugs&#160;</content>- additive effect or potentiation.</paragraph><paragraph><content styleCode="italics">Cholestyramine and colestipol resins&#160;</content>-
Both cholestyramine and colestipol resins have the potential of binding thiazide
diuretics and reducing diuretic absorption from the gastrointestinal tract.</paragraph><paragraph><content styleCode="italics">Corticosteroids, ACTH&#160;</content>- intensified electrolyte
depletion, particularly hypokalemia.</paragraph><paragraph><content styleCode="italics">Pressor
amines (e.g., norepinephrine)&#160;</content>- possible decreased response
to pressor amines but not sufficient to preclude their use.</paragraph><paragraph><content styleCode="italics">Skeletal muscle relaxants, nondepolarizing (e.g., tubocurarine)&#160;-</content>possible increased responsiveness to the muscle relaxant.</paragraph><paragraph><content styleCode="italics">Lithium </content>- generally should not be given with
diuretics. Diuretic agents reduce the renal clearance of lithium and add a
high risk of lithium toxicity. Refer to the package insert for lithium preparations
before use of such preparations with DIURIL.</paragraph><paragraph><content styleCode="italics">Non-steroidal Anti-inflammatory Drugs&#160;</content>-
In some patients, the administration of a non-steroidal anti-inflammatory
agent can reduce the diuretic, natriuretic, and antihypertensive effects of
loop, potassium-sparing and thiazide diuretics. Therefore, when DIURIL and
non-steroidal anti-inflammatory agents are used concomitantly, the patient
should be observed closely to determine if the desired effect of the diuretic
is obtained.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="EABA2FD0-D77A-8BEF-A590-296FE67420B5" />
<code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG AND OR LABORATORY TEST INTERACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml">Drug/Laboratory Interactions</title>
<text><paragraph>Thiazides should be discontinued before carrying out tests
for parathyroid function (see <linkHtml href="#Precautions_General">PRECAUTIONS,
General</linkHtml>).</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="CA0FD2BE-6596-DB7F-A783-1F667DA0B6DC" />
<code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS AND MUTAGENESIS AND IMPAIRMENT OF FERTILITY SECTION" />
<title mediaType="text/x-hl7-title+xml">Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
<text><paragraph>Carcinogenicity studies have not been conducted with chlorothiazide.</paragraph><paragraph>Chlorothiazide
was not mutagenic <content styleCode="italics">in vitro </content>in the Ames
microbial mutagen test (using a maximum concentration of 5<content styleCode="italics" />mg/plate and <content styleCode="italics">Salmonella typhimurium</content> strains TA98 and TA100) and was not mutagenic and did not induce
mitotic nondisjunction in diploid-strains of <content styleCode="italics">Aspergillus
nidulans</content>.</paragraph><paragraph>Chlorothiazide had no adverse effects
on fertility in female rats at doses up to 60<content styleCode="italics" />mg/kg/day and no adverse effects on fertility in male rats at doses
up to 40<content styleCode="italics" />mg/kg/day. These doses are
1.5 and 1.0 times<footnote ID="footnote2"> Calculations based on a human body
weight of 50&#160;kg</footnote> the recommended maximum human dose, respectively,
when compared on a body weight basis.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="Precautions_Pregnancy">
<id root="1BF41DE8-5F89-E5EC-5158-D8B7FA5B5873" />
<code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION" />
<title mediaType="text/x-hl7-title+xml">Pregnancy</title>
<effectiveTime value="20060413" />
<component>
<section>
<id root="9BF7A7D5-F0F2-1A18-2DC8-3E346FC4CB8E" />
<code code="34077-8" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Teratogenic Effects section" />
<title mediaType="text/x-hl7-title+xml">Teratogenic Effects</title>
<effectiveTime value="20060413" />
<component>
<section>
<id root="3E8E205D-6E5D-E684-8F0A-AEBD0B3EA587" />
<title mediaType="text/x-hl7-title+xml">Pregnancy Category C</title>
<text><paragraph>Although reproduction studies performed with chlorothiazide
doses of 50<content styleCode="italics" />mg/kg/day in rabbits, 60<content styleCode="italics" />mg/kg/day in rats and 500<content styleCode="italics" />mg/kg/day in mice revealed no external abnormalities of the fetus
or impairment of growth and survival of the fetus due to chlorothiazide, such
studies did not include complete examinations for visceral and skeletal abnormalities.
It is not known whether chlorothiazide can cause fetal harm when administered
to a pregnant woman; however, thiazides cross the placental barrier and appear
in cord blood. DIURIL should be used during pregnancy only if clearly needed
(see <linkHtml href="#Indications">INDICATIONS AND USAGE</linkHtml>).</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="61EA661D-AAD1-496B-EEF2-B35FCE598EC3" />
<code code="34078-6" codeSystem="2.16.840.1.113883.6.1" codeSystemName="LOINC" displayName="Nonteratogenic Effects section" />
<title mediaType="text/x-hl7-title+xml">Nonteratogenic Effects</title>
<text><paragraph>Chlorothiazide may cause fetal or neonatal jaundice, thrombocytopenia,
and possibly other adverse reactions which have occurred in the adult.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="5B2B13E0-8010-39D6-8738-C6C8A3E3FF72" />
<code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION" />
<title mediaType="text/x-hl7-title+xml">Nursing Mothers</title>
<text><paragraph>Because of the potential for serious adverse reactions in
nursing infants from DIURIL, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance of
the drug to the mother.</paragraph><paragraph ID="_Pediatric_Use" /></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section ID="Pediatric_Use">
<id root="1732041C-9DA7-2700-1662-C48882908684" />
<code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION" />
<title ID="Precautions_PediatricUse" mediaType="text/x-hl7-title+xml">Pediatric Use</title>
<text><paragraph>There are no well-controlled clinical trials in pediatric
patients. Information on dosing in this age group is supported by evidence
from empiric use in pediatric patients and published literature regarding
the treatment of hypertension in such patients. (See <linkHtml href="#Infants_and_Children">DOSAGE
AND ADMINISTRATION, Infants and Children</linkHtml>.)</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="FA267BBB-8FCE-8594-00FA-90D9FF2D2482" />
<code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION" />
<title mediaType="text/x-hl7-title+xml">Geriatric Use</title>
<text><paragraph>Clinical studies of DIURIL did not include sufficient numbers
of subjects aged 65 and over to determine whether they respond differently
from younger subjects. Other reported clinical experience has not identified
differences in responses between the elderly and younger patients. In general,
dose selection for an elderly patient should be cautious, usually starting
at the low end of the dosing range, reflecting the greater frequency of decreased
hepatic, renal, or cardiac function, and of concomitant disease or other drug
therapy.</paragraph><paragraph>This drug is known to be substantially excreted
by the kidney, and the risk of toxic reactions to this drug may be greater
in patients with impaired renal function. Because elderly patients are more
likely to have decreased renal function, care should be taken in dose selection,
and it may be useful to monitor renal function (see <linkHtml href="#Warnings">WARNINGS</linkHtml>).</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="CE1AAB25-524A-536F-1544-20D0D779620A" />
<code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">ADVERSE REACTIONS</content></title>
<text><paragraph>The following adverse reactions have been reported and, within
each category, are listed in order of decreasing severity.</paragraph><paragraph><content styleCode="italics">Body as a Whole:</content> Weakness.</paragraph><paragraph><content styleCode="italics">Cardiovascular:</content> Hypotension including orthostatic
hypotension (may be aggravated by alcohol, barbiturates, narcotics or antihypertensive
drugs).</paragraph><paragraph><content styleCode="italics">Digestive:</content> Pancreatitis,
jaundice (intrahepatic cholestatic jaundice), diarrhea, vomiting, sialadenitis,
cramping, constipation, gastric irritation, nausea, anorexia.</paragraph><paragraph><content styleCode="italics">Hematologic:</content> Aplastic anemia, agranulocytosis,
leukopenia, hemolytic anemia, thrombocytopenia.</paragraph><paragraph><content styleCode="italics">Hypersensitivity:</content> Anaphylactic reactions, necrotizing
angiitis (vasculitis and cutaneous vasculitis), respiratory distress including
pneumonitis and pulmonary edema, photosensitivity, fever, urticaria, rash,
purpura.</paragraph><paragraph><content styleCode="italics">Metabolic:</content> Electrolyte
imbalance (see <linkHtml href="#Precautions">PRECAUTIONS</linkHtml>), hyperglycemia,
glycosuria, hyperuricemia.</paragraph><paragraph><content styleCode="italics">Musculoskeletal:</content> Muscle spasm.</paragraph><paragraph><content styleCode="italics">Nervous
System/Psychiatric:</content> Vertigo, paresthesias, dizziness, headache,
restlessness.</paragraph><paragraph><content styleCode="italics">Renal:</content> Renal
failure, renal dysfunction, interstitial nephritis. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph><paragraph><content styleCode="italics">Skin:</content> Erythema multiforme including Stevens-Johnson
syndrome, exfoliative dermatitis including toxic epidermal necrolysis, alopecia.</paragraph><paragraph><content styleCode="italics">Special Senses:</content> Transient blurred vision, xanthopsia.</paragraph><paragraph><content styleCode="italics">Urogenital:</content> Impotence.</paragraph><paragraph>Whenever
adverse reactions are moderate or severe, thiazide dosage should be reduced
or therapy withdrawn.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="89AF69EC-5790-4B1E-37E9-734EA68701C7" />
<code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">OVERDOSAGE</content></title>
<text><paragraph>The most common signs and symptoms observed are those caused
by electrolyte depletion (hypokalemia, hypochloremia, hyponatremia) and dehydration
resulting from excessive diuresis. If digitalis has also been administered,
hypokalemia may accentuate cardiac arrhythmias.</paragraph><paragraph>In the
event of overdosage, symptomatic and supportive measures should be employed.
Emesis should be induced or gastric lavage performed. Correct dehydration,
electrolyte imbalance, hepatic coma and hypotension by established procedures.
If required, give oxygen or artificial respiration for respiratory impairment.</paragraph><paragraph>The
degree to which chlorothiazide sodium is removed by hemodialysis has not been
established.</paragraph><paragraph>The oral LD<sub>50</sub> of chlorothiazide
is 8.5<content styleCode="italics" />g/kg, greater than 10<content styleCode="italics" />g/kg, and greater than 1<content styleCode="italics" />g/kg, in the mouse, rat and dog respectively.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="6E160E21-0AE5-B4BC-B82F-A8D99FA48C72" />
<code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE AND ADMINISTRATION SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">DOSAGE AND ADMINISTRATION</content></title>
<text><paragraph>Therapy should be individualized according to patient response.
Use the smallest dosage necessary to achieve the required response.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<section>
<id root="4897D26A-F0E1-7645-59AD-C1E5ECDF9835" />
<title mediaType="text/x-hl7-title+xml">Adults</title>
<text />
<effectiveTime value="20060413" />
<component>
<section>
<id root="E77C10C4-9A2B-04BB-EE3C-6D30DA543621" />
<title mediaType="text/x-hl7-title+xml">For Edema</title>
<text><paragraph>The usual adult dosage is 0.5 to 1.0<content styleCode="italics" />g (10 to 20&#160;mL) once or twice a day. Many patients with edema
respond to intermittent therapy, i.e., administration on alternate days or
on three to five days each week. With an intermittent schedule, excessive
response and the resulting undesirable electrolyte imbalance are less likely
to occur.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
<component>
<section>
<id root="B7FF3E86-D8CA-1CEE-1F40-26DFDBBFF594" />
<title mediaType="text/x-hl7-title+xml">For Control of Hypertension</title>
<text><paragraph>The usual adult starting dosage is 0.5 or 1.0<content styleCode="italics" />g (10 to 20&#160;mL) a day as a single or divided dose. Dosage is
increased or decreased according to blood pressure response. Rarely some patients
may require up to 2.0<content styleCode="italics" />g (40&#160;mL)
a day in divided doses.</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
<component>
<section>
<id root="EE9EE8F5-E925-6A20-3C07-73A757D49E61" />
<title ID="Infants_and_Children" mediaType="text/x-hl7-title+xml">Infants and Children</title>
<effectiveTime value="20060413" />
<component>
<section>
<id root="B06A5980-1456-E1C6-3BE4-F3097933D568" />
<title mediaType="text/x-hl7-title+xml">For Diuresis and For Control of Hypertension</title>
<text><paragraph>The usual pediatric dosage is 5 to 10&#160;mg per pound (10
to 20&#160;mg/kg) per day in single or two divided doses, not to exceed 375&#160;mg
per day (2.5 to 7.5&#160;mL or &#189; to 1&#189; teaspoonfuls of the oral
suspension daily) in infants up to 2 years of age or 1&#160;g per day in children
2 to 12 years of age. In infants less than 6 months of age, doses up to 15&#160;mg
per pound (30&#160;mg/kg) per day in two divided doses may be required. (See <linkHtml href="#Precautions_PediatricUse">PRECAUTIONS, Pediatric Use</linkHtml>)</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
</section>
</component>
<component>
<section>
<id root="D0C65C8F-0F7B-7CEF-60C5-F7C86ABDCA77" />
<code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION" />
<title mediaType="text/x-hl7-title+xml"><content styleCode="bold">HOW SUPPLIED</content></title>
<text><paragraph>No. 3239 &#8212; Oral Suspension DIURIL, 250&#160;mg of
chlorothiazide per 5&#160;mL, is a yellow, creamy suspension, and is supplied
as follows:</paragraph><paragraph><content styleCode="bold">NDC</content> 0006-3239-66
bottles of 237&#160;mL.</paragraph></text>
<effectiveTime value="20060413" />
<component>
<section>
<id root="A7F15F32-ABDE-E3C0-1BF8-2D28367EFCF1" />
<title mediaType="text/x-hl7-title+xml">Storage</title>
<text><paragraph>Oral Suspension DIURIL: Keep container tightly closed. Protect
from freezing, &#8211;20&#176;C (&#8211;4&#176;F) and store at room temperature,
15-30&#176;C (59-86&#176;F).</paragraph><br /><paragraph>Merck &amp; Co., Inc.,
Whitehouse Station, NJ 08889, USA</paragraph><br /><br /><paragraph>Printed in USA</paragraph><paragraph>7897961</paragraph></text>
<effectiveTime value="20060413" />
</section>
</component>
</section>
</component>
</structuredBody>
</component>
</document>
